Table 1.
Demographic and clinical characteristics for experimental (EXP) and self-report participants (S-R)a.
| Schizophrenia Smokers |
Control Smokers |
p-value | |||
|---|---|---|---|---|---|
| EXP (n = 16) |
S-R (n = 43) |
EXP (n = 12) |
S-R (n = 28) |
||
| Recruitment Source | |||||
| CTNMH Volunteer Database | 50% | 63% | – | – | NA |
| ASRB Volunteer Database | 19% | 22% | – | – | NA |
| HMRI Volunteer Database | – | – | 25% | – | NA |
| Media | 19% | – | 25% | 7% | NA |
| Flyers | 12% | 9% | 50% | 93% | NA |
| Schizophrenia Fellowship | – | 6% | – | – | NA |
| Ageb | 43 (10.8) | 43 (9.78) | 37.6 (11.9) | 37.68 (8.77) | .025⁎ |
| Gender (% Male) | 56.3 | 48.8 | 50.0 | 35.7 | < .001 |
| WTAR Estimated Full-Scale IQb | 99.1 (7.2) | 104.3 (5.7) | .05⁎ | ||
| Self-reported age of illness onsetb | 21.87 (6.09) | 19.08 (4.22) | NA | NA | .11 |
| Duration | 21.13 (9.19) | 24.97 (9.67) | NA | NA | .19 |
| Antipsychotic classc | NA | NA | – | ||
| Atypical | 12 | 35 | NA | NA | |
| Typical | 2 | 9 | NA | NA | |
| CPZ equivalents (mg/day)b | 363.62 (293.66) | 612.05 (466.98) | NA | NA | .03⁎ |
Note. ASRB = Australian Schizophrenia Research Bank; CTNMH = Centre for Translational Neuroscience and Mental Health Research; CPZ = chlorpromazine; HMRI = Hunter Medication Research Institute; WTAR = Weschler Test of Adult Reading.
a
Values are expressed as a percentage of the group unless otherwise specified.
b
Values are expressed as mean (SD).
c
Values are expressed as the total number of participants.
⁎
Significant at p < .05.